作者: Camila Rizek , Juliana Rosa Ferraz , Inneke Marie van der Heijden , Mauro Giudice , Anna Karina Mostachio
DOI: 10.1016/J.JIAC.2014.10.009
关键词:
摘要: Abstract Background The aim of this study was to evaluate the in vitro susceptibility MDR gram-negatives bacteria old drugs such as polymyxin B, minocycline and fosfomycin new tigecycline. Methods One hundred fifty-three isolates from 4 Brazilian hospitals were evaluated. Forty-seven Acinetobacter baumannii resistant carbapenens harboring adeB, blaOxA23, blaOxA51, blaOxA143 blaIMP genes, 48 Stenotrophomonas maltophilia including levofloxacin and/or trimethoprim-sulfamethoxazole sul-1, sul-2 qnrMR 8 Serratia marcescens 50 Klebsiella pneumoniae blaKPC-2 tested determine their minimum inhibitory concentrations (MICs) by microdilution following drugs: minocycline, ampicillin-sulbactam, tigecycline, B agar dilution according with breakpoint criteria CLSI EUCAST (fosfomycin). In addition, for Pseudomonas spp. applied spp S. maltophilia, FDA tigecycline used S. maltophilia criterion S. maltophilia. Results Tigecycline showed best activity against gram-negative evaluated, followed fosfomycin. Polymyxin resistance among K. pneumoniae detected in 6 isolates, using MIC > 8 ug/mL. Two these Minocycline only A. baumannii excellent both. Conclusions Fosfomycin seems not be an option treat infections due breakpoint, on other hand, S. marcescens K. pneumoniae.